keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/29346783/does-2-pro-prostate-specific-antigen-meet-the-criteria-to-justify-its-inclusion-in-the-clinical-decision-making-process
#1
Angeles Sanchis-Bonet, Marta Barrionuevo-González, Ana Bajo-Chueca, Nelson Morales-Palacios, Manuel Sanchez-Chapado
INTRODUCTION: To assess whether [-2]pro-prostate-specific antigen (p2PSA) meets the criteria to justify its inclusion in a predictive model of prostate cancer (PCa) diagnosis and in the clinical decision-making process. MATERIALS AND METHODS: A total 172 men with total prostate-specific antigen of 2-10 ng/mL underwent measurement of free PSA and p2PSA before prostate biopsy in an observational and prospective study. From these measurements, the Prostate Health Index (PHI) was calculated...
January 18, 2018: Urologia Internationalis
https://www.readbyqxmd.com/read/29343039/-development-of-a-chinese-nomogram-based-on-muti-parametric-magnetic-resonance-for-predicting-the-probability-of-prostate-cancer-in-patients-after-initial-negative-biopsy
#2
C Huang, G J Ji, G Song, H Wang, Y K Chen, L Q Zhou
Objective: To develop a predictive nomogram based on multi-parametric magnetic resonance imaging (mpMRI) information to identify men more likely to have a cancer diagnosed on repeat prostate biopsy. Methods: The clinical data of 237 patients who received repeat prostate biopsy after initial negative biopsy from Department of Urology of Peking University First Hospital between January 2001 and August 2016 was reviewed. Patient age, body mass index (BMI), serum total prostate-specific antigen (PSA), percent free PSA (f/t), prostate volume (PV), PSA density (PSAD), PSA velocity (PSAV), digital rectal examination (DRE), transrectal ultrasound (TRUS)and mpMRI results were included in the univariate and multivariate analysis...
January 9, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29338305/safety-and-feasibility-of-prostate-stereotactic-ablative-radiotherapy-using-multi-modality-imaging-and-flattening-filter-free
#3
Aileen Duffton, Azmat Sadozye, Lynsey Devlin, Nicholas MacLeod, Carolynn Lamb, Suzanne Smith, Philip McLoone, Muthu Sankaralingam, John Foster, Stephanie Paterson, Stefanie Keatings, David Dodds
PURPOSE: To investigate feasibility and safety of SABR in the management of prostate cancer while employing MR/CT fusion for delineation, fiducial markers seeds for positioning and Varian Rapidarc with FFF delivery. METHODS: Forty-one patients were treated for low-intermediate risk prostate cancer with initial PSA (iPSA) of ≤20ng/ml, Gleason score 6-7. Patients had MR/CT fusion for delineation of prostate +/-seminal vesicles. CT/MR fusion images were used for delineation and planned using flattening filter free modality...
January 17, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29319928/low-dose-rate-brachytherapy-for-prostate-cancer-outcomes-beyond-10-years-of-follow-up
#4
S Lazarev, M R Thompson, N N Stone, R G Stock
OBJECTIVES: To examine biochemical control, survival, and late morbidity with definitive low-dose-rate brachytherapy (LDR-BT) for prostate cancer patients surviving ≥10 years post-treatment. MATERIALS AND METHODS: We identified 757 men with localized prostate cancer who underwent definitive LDR-BT in the period 1990-2006 and were followed for ≥10 years at our institution. Biochemical failure-free survival (BFFS), distant metastases-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were selected as study endpoints...
January 10, 2018: BJU International
https://www.readbyqxmd.com/read/29285775/systemic-immune-inflammation-index-predicts-the-combined-clinical-outcome-after-sequential-therapy-with-abiraterone-and-docetaxel-for-metastatic-castration-resistant-prostate-cancer-patients
#5
Liancheng Fan, Rui Wang, Chenfei Chi, Wen Cai, Yong Zhang, Hongyang Qian, Xiaoguang Shao, Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Lixin Zhou, Baijun Dong, Wei Xue
OBJECTIVE: To compare the antitumor effect of abiraterone (AA) followed by docetaxel-prednisone (DP) or vice versa in metastatic castration-resistant prostate cancer (mCRPC) patients, and explored factors that might predict combined PSA-PFS, combined rPFS and OS. PATIENTS AND METHODS: We retrospectively analyzed mCRPC patients treated with sequential therapy using DP followed by AA or vice versa. Patients who had received enzalutamide or cabazitaxel were excluded...
December 29, 2017: Prostate
https://www.readbyqxmd.com/read/29275406/pathologic-outcomes-of-candidates-for-active-surveillance-undergoing-radical-prostatectomy-results-from-a-contemporary-turkish-patient-cohort
#6
Ilker Tinay, Güven Aslan, Ali Riza Kural, Haluk Özen, Bülent Akdoğan, Asıf Yıldırım, Şakir Ongün, Alp Özkan, Tarik Esen, Ferruh Zorlu, Özdal Dillioğlugil, Nural Bekiroglu, Levent Türkeri
INTRODUCTION: To evaluate the pathological outcomes of Turkish men meeting the criteria for Active Surveillance (AS), who elected to undergo immediate radical prostatectomy (RP). MATERIAL AND METHODS: Retrospective analysis including 1,212 patients with clinically localized prostate cancer (PCa) who met the eligibility criteria for AS. The primary outcomes were pathological upstaging and pathological upgrading. RESULTS: Nine hundred ninety-one patients were eligible for analysis after the central review of the submitted data...
December 22, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/29261439/targeting-androgen-receptor-and-dna-repair-in-metastatic-castration-resistant-prostate-cancer-results-from-nci-9012
#7
Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, Costantine Albany, Mark N Stein, Lakshmi P Kunju, Javed Siddiqui, Yi-Mi Wu, Dan Robinson, Robert J Lonigro, Xuhong Cao, Scott A Tomlins, Rohit Mehra, Kathleen A Cooney, Bruce Montgomery, Emmanuel S Antonarakis, Daniel H Shevrin, Paul G Corn, Young E Whang, David C Smith, Megan V Caram, Karen E Knudsen, Walter M Stadler, Felix Y Feng, Arul M Chinnaiyan
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients and Methods Patients underwent metastatic site biopsy and were stratified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ETS fusions predicted response...
December 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29259293/prostate-specific-antigen-psa-density-in-the-diagnostic-algorithm-of-prostate-cancer
#8
Tobias Nordström, Olof Akre, Markus Aly, Henrik Grönberg, Martin Eklund
BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) alone leads to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early evidence on its use for biopsy decisions was conflicting and use of PSA density is not commonly recommended in guidelines. METHODS: We analyzed biopsy outcomes in 5291 men in the population-based STHLM3 study with PSA ≥ 3 ng/ml and ultrasound-guided prostate volume measurements by using percentages and regression models...
December 19, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29213237/effectiveness-of-deferred-combined-androgen-blockade-therapy-predicts-efficacy-in-abiraterone-acetate-treated-metastatic-castration-resistant-prostate-cancer-patients-after-docetaxel
#9
Jian-Ri Li, Kun-Yuan Chiu, Shian-Shiang Wang, Cheng-Kuang Yang, Chuan-Shu Chen, Hao-Chung Ho, Chi-Feng Hung, Chen-Li Cheng, Chi-Rei Yang, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Chao-Hsiang Chang, Chiann-Yi Hsu, Yen-Chuan Ou
Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic castration resistant prostate cancer. In this study, we attempt to analyze the role of conventional anti-androgen drugs as deferred CAB therapy in castration-resistant prostate cancer patients. Materials and Methods: From 2012 to 2017, 48 metastatic castration-resistant prostate cancer (CRPC) patients who received sequential treatments with primary androgen blockade, oral anti-androgen regimens, and docetaxel followed by AA treatment were included...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29211355/tumor-marker-%C3%AE-fetoprotein-receptor-does-not-discriminate-between-benign-prostatic-disease-and-prostate-cancer
#10
Tomaž Smrkolj, Borut Gubina, Jure Bizjak, Kristina Kumer, Teja Fabjan, Joško Osredkar
BACKGROUND: The α-fetoprotein receptor (RECAF) is a proposed novel tumor marker for detecting several different types of tumors, including prostate cancer (PCa). OBJECTIVES: The aim of the study was to evaluate RECAF in discriminating benign prostatic conditions from PCa and to compare it with prostate-specific antigen (PSA). MATERIAL AND METHODS: A total of 64 patients with elevated serum PSA levels and/or abnormal digital rectal examination of the prostate referred to a tertiary center for transrectal ultrasound (TRUS) biopsy of the prostate were prospectively enrolled in the study from January 2009 to April 2010...
October 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29208480/robotic-stereotactic-retreatment-for-biochemical-control-in-previously-irradiated-patients-affected-by-recurrent-prostate-cancer
#11
M Loi, V Di Cataldo, G Simontacchi, B Detti, P Bonomo, L Masi, I Desideri, D Greto, G Francolini, V Carfora, D Pezzulla, M Perna, G A Carta, L Livi
AIMS: Robotic stereotactic body radiotherapy (rSBRT) to local recurrences emerged as a valuable option for exclusive local failure after prior external beam radiation therapy (EBRT) for localised prostate cancer. The aim of this study was to assess the efficacy and safety of rSBRT in patients experiencing locally recurrent prostate cancer after prior definitive or postoperative radiotherapy using the Cyberknife. MATERIALS AND METHODS: Data from 50 patients were retrospectively reviewed...
December 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29181556/oligometastases-in-prostate-cancer-metabolic-response-in-follow-up-psma-pet-cts-after-hypofractionated-igrt
#12
René Baumann, Mark Koncz, Ulf Luetzen, Fabian Krause, Juergen Dunst
BACKGROUND: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMAPET/CT) is a new and evolving diagnostic method in prostate cancer with special impact on treatment planning in image-guided radiotherapy (IGRT). Initial results of metabolic response in repeated PSMA PET/CTs after hypofractionated IGRT for metastatic lesions are reported here. MATERIALS AND METHODS: Of 280 patients investigated with 68Ga-PSMA PET/CT in the period from 01/2014 through 12/2016 in the authors' department, patients were selected according to the following criteria: oligometastatic disease at initial PSMA PET/CT defined as not more than five metastatic lesions, hypofractionated IGRT to all lesions, no systemic therapy in the last 6 months and during follow-up, and at least one follow-up PSMA PET after radiotherapy...
November 27, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29174470/associations-between-prostate-volume-and-oncologic-outcomes-in-men-undergoing-focal-cryoablation-of-the-prostate
#13
Ahmed Elshafei, Kae Jack Tay, Onder Kara, Ercan Malkoc, Yaw Nyame, Hans Arora, Asmaa Hatem, Sahil A Patel, Franco Lugnani, Thomas J Polascik, J Stephen Jones
INTRODUCTION: The purpose of this study was to assess the relationship of total prostate volume (TPV) and oncologic outcomes following focal prostate cryoablation. MATERIALS AND METHODS: A query of the Cryo On-Line Database (COLD) registry for men who underwent primary focal prostate cryoablation revealed 829 patients with complete data. The impact of TPV on oncologic outcomes including progression-free survival (PFS) and post-cryoablation biopsy outcome was assessed using Kaplan-Meier curves and Cox and logistic regression models...
October 28, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29173976/phase-2-study-of-weekly-paclitaxel-plus-estramustine-in-metastatic-hormone-refractory-prostate-carcinoma-ecog-acrin-cancer-research-group-e1898-trial
#14
Yu-Ning Wong, Judith Manola, Gary R Hudes, Bruce J Roth, Judd W Moul, Andrea M Barsevick, Richard M Scher, Michael J Volk, David J Vaughn, Stephen D Williams, Michael J Fisch, David Cella, Michael A Carducci, George Wilding
INTRODUCTION: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: We enrolled 77 patients who had received no prior chemotherapy for CRPC between 1998 and 2000; a total of 74 subjects were eligible for the study. Each 8-week cycle included paclitaxel 90 mg/m2 provided intravenously weekly for 6 weeks, followed by 2 weeks off therapy and oral estramustine 280 mg twice daily for 3 days beginning 24 hours before the first dose of paclitaxel...
October 16, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29164346/impact-of-prior-androgen-receptor-axis-targeted-agents-on-the-clinical-activity-of-subsequent-docetaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-comparative-assessment-between-abiraterone-acetate-and-enzalutamide
#15
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama, Atsushi Otsuka
The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This study included a total of 114 mCRPC patients consisting of 54 and 60 who progressed following treatment with AA and Enz, respectively, prior to the introduction of docetaxel, and compared oncological outcomes with docetaxel between these two groups...
November 21, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29164326/men-with-family-history-of-prostate-cancer-have-a-higher-risk-of-disease-recurrence-after-radical-prostatectomy
#16
Mark Thalgott, Martina Kron, Johannes M Brath, Donna P Ankerst, Ian M Thompson, Juergen E Gschwend, Kathleen Herkommer
PURPOSE: We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP). METHODS: Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed...
November 21, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29156544/endogenous-sphingolipid-signaling-pathway-implicated-in-the-action-of-croton-membranaceus-on-the-prostate-gland-in-bph-patients
#17
George Awuku Asare, Yvonne Anang, Daniel K Afriyie, Brodrick Yeboah Amoah, Bernice Asiedu, Derek Doku, Hannah Serwah Ocansey, Nana Yaw Odei Danso, Prince Tekpor, Sarah Osam
Background: Croton membranaceus extract has apoptotic effects on BPH-1 cells. This study determined if the apoptotic effects were created through the ceramide pathway. Methods: The study was a follow-up to a previous observational study of 30 histologically confirmed patients with benign prostatic hyperplasia (BPH) who were on C. membranaceus ethanolic extract at 20 mg t.i.d orally for 3 mo. Thereafter, total and free prostate-specific antigen (PSA), lipid profile plus Apo lipoprotein A and B, ceramide/Sphingophospho-kinase 1 (SphK1) and 2 (SphK2), sphingosine lyase (SPL), the cytotoxic adducts of oxidative stress 4-hydroxy-2-nonenal (4HNE) and malondialdehyde (MDA), were determined...
November 18, 2017: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/29137895/a-four-kallikrein-panel-and-%C3%AE-microseminoprotein-in-predicting-high-grade-prostate-cancer-on-biopsy-an-independent-replication-from-the-finnish-section-of-the-european-randomized-study-of-screening-for-prostate-cancer
#18
Melissa Assel, Liisa Sjöblom, Teemu J Murtola, Kirsi Talala, Paula Kujala, Ulf-Håkan Stenman, Kimmo Taari, Anssi Auvinen, Andrew Vickers, Tapio Visakorpi, Teuvo L Tammela, Hans Lilja
BACKGROUND: A panel of four kallikrein markers (total, free, and intact prostate-specific antigen [PSA] and human kallikrein-related peptidase 2 [hK2]) improves predictive accuracy for Gleason score ≥7 (high-grade) prostate cancer among men biopsied for elevated PSA. A four-kallikrein panel model was originally developed and validated by the Dutch center of the European Randomized Study of Screening for Prostate Cancer (ERSPC). The kallikrein panel is now commercially available as 4Kscore™...
November 11, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29126389/safety-and-efficacy-of-abiraterone-acetate-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer-an-italian-multicenter-real-life-study
#19
Luca Cindolo, Clara Natoli, Cosimo De Nunzio, Michele De Tursi, Maurizio Valeriani, Silvana Giacinti, Salvatore Micali, Mino Rizzo, Giampaolo Bianchi, Eugenio Martorana, Marcello Scarcia, Giuseppe Mario Ludovico, Pierluigi Bove, Anastasia Laudisi, Oscar Selvaggio, Giuseppe Carrieri, Maida Bada, Pietro Castellan, Stefano Boccasile, Pasquale Ditonno, Paolo Chiodini, Paolo Verze, Vincenzo Mirone, Luigi Schips
BACKGROUND: To evaluate the safety and efficacy of abiraterone acetate (AA) in the "real life" clinical practice for men with chemotherapy-naïve metastatic castration-resistant prostate. METHODS: A consecutive series of patients with mCRPC in 9 Italian tertiary centres treated with AA was collected. Demographics, clinical parameters, treatment outcomes and toxicity were recorded. The Brief Pain Inventory scale Q3 was tracked and patient treatment satisfaction was evaluated...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29094386/characteristics-and-outcome-of-prostate-cancer-patients-with-overall-biopsy-gleason-score-3-4-7-and-highest-gleason-score-3-4-7-or-3-4-7
#20
Esther I Verhoef, Charlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, Chris H Bangma, Luca Incrocci, Theodorus H van der Kwast, Monique J Roobol, Geert J van Leenders
AIM: Prostate cancer heterogeneity and multifocality might result in different Gleason scores (GS) at individual biopsy cores. According to WHO/ISUP guidelines, the GS in each biopsy core should be recorded with optional reporting of overall GS for the entire case. We aimed to compare the clinicopathologic characteristics and outcome of men with overall biopsy GS 3+4=7 with highest GS 3+4=7 (HI=OV) to those with highest GS > 3+4=7 (HI>OV). METHODS AND RESULTS: Prostate cancer biopsies from the European Randomized Study of Screening for Prostate Cancer (ERSPC) were revised according to WHO/ISUP 2014 guidelines (n=1031)...
November 1, 2017: Histopathology
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"